

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Comparison of the effect Sprays of flucocyan, boudsonide and mometazone in patients with nasal-sinus polyposis after sinus endoscopic surgery

#### Protocol summary

##### Study aim

Comparison of the effect of fluticasone spray and budesonide spray and mometasone spray in patients with nasal-sinus polyposis after endoscopic sinus surgery.

##### Design

Clinical trial with control group, with parallel group; double blind, randomized

##### Settings and conduct

This study is performed in Valiasr Hospital of Birjand, South Khorasan Province. 96 patients are randomly divided into three intervention groups one to three (A-C). Questions related to the effectiveness of the spray before and after treatment will be asked and evaluated by the ward nurse.

##### Participants/Inclusion and exclusion criteria

Inclusion criterion includes having informed consent. Exclusion criteria include: having allergic rhinitis, eye disease, known immunodeficiency disease, infectious symptoms including purulent discharge from the back of the throat and nose.

##### Intervention groups

The intervention groups are as follows: Group A received fluticasone nasal spray twice daily (50 micrograms per puff). Group B receive budesonide spray twice daily (50 micrograms per puff). Group C receive mometasone spray twice daily (50 micrograms per puff).

##### Main outcome variables

Runny nose, improvement of symptoms compared to before taking the drug, clinical symptoms include: headache, nasal congestion, sinus pain, PND, pain around the eyes, pus in the nose, cough, runny nose and decreased sense of smell

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190618043934N7**  
Registration date: **2020-08-04, 1399/05/14**  
Registration timing: **registered\_while\_recruiting**

Last update: **2020-08-04, 1399/05/14**

Update count: **0**

##### Registration date

2020-08-04, 1399/05/14

##### Registrant information

##### Name

Zabihullah Mohaghegh

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 56 3232 3232

##### Email address

oabstudent@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-06-30, 1399/04/10

##### Expected recruitment end date

2020-09-20, 1399/06/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparison of the effect Sprays of flucocyan, boudsonide

and mometasone in patients with nasal-sinus polyposis after sinus endoscopic surgery

**Public title**

The effect of fluticasone, budesonide and mometasone on nasal polyposis

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with chronic rhinosinusitis with nasal polyps who have undergone sinus endoscopic surgery. Patients aged 15 to 70 years Having conscious satisfaction

**Exclusion criteria:**

Existence of eye disease Existence of known immunodeficiency disease Infectious symptoms include purulent discharge from the back of the throat and nose Having Allergic rhinitis

**Age**

No age limit

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Outcome assessor

**Sample size**

Target sample size: **32**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The placement of individuals in each group will be randomly simple and blocked, which will be in one of three groups A (fluticasone spray), intervention B (budsonide spray) or group C (mometasone spray). First, various triple blocks are created on different cards (ABC, CAB, CBA, BCA, BAC and ACB). One of these blocks is randomly selected and patients will be divided into one of three groups A, B or C. Then randomization is performed for other patients.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

Outcome Assessor: The ward nurse, without knowing the type of medication received, questions the patients and records them in the relevant checklist.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Birjand University of Medical Sciences

**Street address**

Ghaffari Str

**City**

Birjand

**Province**

South Khorasan

**Postal code**

9717811674

**Approval date**

2020-07-13, 1399/04/23

**Ethics committee reference number**

IR.BUMS.REC.1399.166

**Health conditions studied****1****Description of health condition studied**

Nasal polyps

**ICD-10 code**

J33

**ICD-10 code description**

Nasal polyp

**Primary outcomes****1****Description**

Runny nose

**Timepoint**

runny nose before and After treatment.

**Method of measurement**

By asking the patient.

**2****Description**

headache

**Timepoint**

headache before and After treatment.

**Method of measurement**

By asking the patient.

**3****Description**

nasal congestion before and After treatment.

**Timepoint**

nasal congestion

**Method of measurement**

By asking the patient.

**4****Description**

sinus pain

**Timepoint**

sinus pain before and After treatment.

**Method of measurement**

By asking the patient.

**5****Description**

pain around the eyes

**Timepoint**

pain around the eyes before and After treatment.

**Method of measurement**

By asking the patient.

**6****Description**

pus in the nose

**Timepoint**

pus in the nose before and After treatment.

**Method of measurement**

By asking the patient.

**7****Description**

cough

**Timepoint**

cough before and After treatment.

**Method of measurement**

By asking the patient.

**8****Description**

Decreased sense of smell Before and After Treatment.

**Timepoint**

Decreased sense of Smell Before and After Treatment.

**Method of measurement**

By Asking The Patient.

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group 1: Group A receiving fluticasone nasal spray twice a day, 0.1 mg (manufactured by Jaber Bin Hayan Pharmaceutical Company) for 4 weeks.

**Category**

Treatment - Drugs

**2****Description**

Intervention group 2: Group B receiving Budesonide nasal spray twice a day, 0.1 mg (manufactured by Jaber Bin Hayan Pharmaceutical Company) for 4 weeks.

**Category**

Treatment - Drugs

**3****Description**

Intervention group 3: Group C receiving Mometasone nasal spray twice a day, 0.1 mg (manufactured by Jaber Bin Hayan Pharmaceutical Company) for 4 weeks.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

ValieAsr Hospital

**Full name of responsible person**

Haniye Sadat Razavi

**Street address**

Ghaffari Str

**City**

Birjand

**Province**

South Khorasan

**Postal code**

9717811674

**Phone**

+98 56 3232 3232

**Email**

oabstudent@gmail.com

**Web page address****Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Birjand University of Medical Sciences

**Full name of responsible person**

Dr. Tooba Kazemi

**Street address**

Ghaffari Str

**City**

Birjand

**Province**

South Khorasan

**Postal code**

9717811674

**Phone**

+98 56 3238 1200

**Email**

oabstudent@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Birjand University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Birjand University of Medical Sciences

**Full name of responsible person**

Zabihullah Mohaghegh

**Position**

Student

**Latest degree**

Bachelor

**Other areas of specialty/work**

General Practitioner

**Street address**

Ghaffari Str

**City**

Birjand

**Province**

South Khorasan

**Postal code**

9717811674

**Phone**

+98 56 3232 3232

**Email**

oabstudent@gmail.com

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Birjand University of Medical Sciences

**Full name of responsible person**

Dr. Masoud Asghari

**Position**

Science Committee

**Latest degree**

Specialist

**Other areas of specialty/work**

Ear, Nose, and Throat

**Street address**

Ghaffari Str

**City**

Birjand

**Province**

South Khorasan

**Postal code**

9717811674

**Phone**

+98 56 3232 3232

**Email**

oabstudent@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Birjand University of Medical Sciences

**Full name of responsible person**

Zabihullah Mohaghegh

**Position**

Student

**Latest degree**

Bachelor

**Other areas of specialty/work**

General Practitioner

**Street address**

Moallem Str

**City**

Birjand

**Province**

South Khorasan

**Postal code**

9717811674

**Phone**

+98 56 3232 3232

**Email**

oabstudent@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no need to publish individual patient information

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available